Search

Your search keyword '"Lee, Kyoung Bun"' showing total 338 results
Start Over Author "Lee, Kyoung Bun"
338 results on '"Lee, Kyoung Bun"'

2. Prognostic Evaluation and Survival Prediction for Combined Hepatocellular-Cholangiocarcinoma Following Hepatectomy.

Author

Chun, Seok-Joo, Jung, Yu Jung, Choi, YoungRok, Yi, Nam-Joon, Lee, Kwang-Woong, Suh, Kyung-Suk, Lee, Kyoung Bun, Kang, Hyun-Cheol, Chie, Eui Kyu, and Kim, Kyung Su

Subjects
PROGRESSION-free survival, OVERALL survival, PROGNOSIS, CANCER relapse, HEPATECTOMY
Abstract

Purpose: This study aimed to assess prognostic factors associated with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to predict 5-year survival based on these factors. Materials and Methods: Patients who underwent definitive hepatectomy from 2006 to 2022 at a single institution was retrospectively analyzed. Inclusion criteria involved a pathologically confirmed diagnosis of cHCC-CCA. Results: A total of 80 patients with diagnosed cHCC-CCA were included in the analysis. The median progression-free survival was 15.6 months, while distant metastasis-free survival (DMFS), hepatic progression-free survival, and overall survival (OS) were 50.8, 21.5, and 85.1 months, respectively. In 52 cases of recurrence, intrahepatic recurrence was the most common initial recurrence (34/52), with distant metastasis in 17 cases. Factors associated with poor DMFS included tumor necrosis, lymphovascular invasion (LVI), perineural invasion, and histologic compact type. Postoperative carbohydrate antigen 19-9, tumor necrosis, LVI, and close/positive margin were associated with poor OS. LVI emerged as a key factor affecting both DMFS and OS, with a 5-year OS of 93.3% for patients without LVI compared to 35.8% with LVI. Based on these factors, a nomogram predicting 3-year and 5-year DMFS and OS was developed, demonstrating high concordance with actual survival in the cohort (Harrell C-index 0.809 for OS, 0.801 for DMFS, respectively). Conclusion: The prognosis of cHCC-CCA is notably poor when combined with LVI. Given the significant impact of adverse features, accurate outcome prediction is crucial. Moreover, consideration of adjuvant therapy may be warranted for patients exhibiting poor survival and increased risk of local recurrence or distant metastasis. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer.

Author

Jung, Hye‐Sol, Kwon, Wooil, Yun, Won‐Gun, Paik, Woo Hyun, Hyub Lee, Sang, Ryu, Ji Kon, Oh, Do‐Youn, Lee, Kyoung Bun, Chie, Eui Kyu, and Jang, Jin‐Young

Abstract

Background: Neoadjuvant treatment (NAT) is standard for borderline resectable pancreatic cancer (BRPC). However, consensus is lacking on the optimal surgical timing for patients with BRPC undergoing NAT. The aim of this study was to investigate the long‐term outcomes of patients undergoing NAT for BRPC and suggest optimal resection timing. Methods: Prospectively collected data for 282 patients with BRPC between January 2007 and December 2019 were retrospectively reviewed. There were 164 patients who underwent NAT followed by surgery, 45 for chemotherapy only, and 73 for upfront surgery. Among them, 150 patients who underwent R0 or R1 resection following NAT were investigated to identify prognostic factors. Results: Patients receiving NAT followed by surgery showed the best survival (median overall survival [OS]; NAT followed by surgery vs. upfront surgery vs. chemotherapy only; 35 vs. 23 vs. 16 months). In the NAT group, 54 (36.0%) patients received less than 3 months of NAT, 68 (45.3%) received ≥3, <6 months, and 28 (18.7%) received longer than 6 months. Patients receiving ≥3 months of NAT showed an improved OS compared to <3 months (median; not reached vs. 27 months). In the FOLFIRINOX group, patients who received more than eight FOLFIRINOX cycles showed a good prognosis (<6 vs. 6–7 vs. ≥8 cycles; median survival, 26 vs. 41 months vs. not‐reached). However, >12 cycles did not carry a survival benefit compared to 8–11 cycles. Conclusion: The optimal resection timing following NAT is once a patient undergoes at least 3 months of neoadjuvant chemotherapy or at least eight FOLFIRINOX cycles. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations

Author

Park, Eujin, Kang, Hee Gyung, Choi, Young Hun, Lee, Kyoung Bun, Moon, Kyung Chul, Jeong, Hyeon Joo, and Nagata, Michio

Subjects
Research, Risk factors, Gene mutation -- Research, Kidney diseases -- Risk factors -- Research
Abstract

Author(s): Eujin Park [sup.1] , Hee Gyung Kang [sup.1] [sup.2] , Young Hun Choi [sup.3] , Kyoung Bun Lee [sup.4] , Kyung Chul Moon [sup.4] [sup.5] , Hyeon Joo Jeong [...], Background Mutations in the AarF domain containing kinase 4 gene (ADCK4), one of the novel genes causing steroid-resistant nephrotic syndrome (SRNS), usually manifest as isolated adolescent-onset focal segmental glomerulosclerosis (FSGS). ADCK4 interacts with components of the coenzyme Q10 (CoQ10) biosynthesis pathway. Methods The incidence and phenotypes of patients with ADCK4 mutations were investigated in a cohort of Korean pediatric patients with SRNS. Results Among the 53 patients enrolled in the study the incidence of ADCK4-associated FSGS was 7.5% (n = 4) in children aged 5 years and older with multidrug-resistant FSGS. Two additional patients were included for phenotype analyses, one detected by family screening and the other with cyclosporine-responsive FSGS. These six patients presented proteinuria without overt nephrotic syndrome at a median age of 110 (range 60-153) months, of whom five progressed to end-stage renal disease within a median period of 46 (range 36-79) months after onset. Renal biopsies revealed mitochondrial abnormalities in podocytes and tubular cells of all patients. Notably, all patients showed accompanying medullary nephrocalcinosis. None of the patients showed other extrarenal manifestations. Conclusions ADCK4 mutations should be considered in older children presenting with steroid resistant FSGS. An early diagnosis of ADCK4 mutations is essential because the condition is treatable with CoQ10 supplementation at an early stage. The association with medullary nephrocalcinosis may be an additional diagnostic indicator.

Published
2017
Full Text
View/download PDF

23. Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival

Author

Vijayakurup, Vinod, primary, Maeng, Kyungah, additional, Lee, Hye Seung, additional, Meyer, Benjamin, additional, Burkett, Sandra, additional, Nawab, Akbar, additional, Dougherty, Michael W., additional, Jobin, Christian, additional, Mahmud, Iqbal, additional, Garrett, Timothy J., additional, Feely, Michael, additional, Lee, Kyoung Bun, additional, Kaye, Frederic J., additional, Guijarro, Maria V., additional, and Zajac-Kaye, Maria, additional

Published
2022
Full Text
View/download PDF

32. LI-RADS Tumor in Vein at CT and Hepatobiliary MRI

Author

Bae, Jae Seok, primary, Lee, Jeong Min, additional, Jeon, Sun Kyung, additional, Yoo, Jeongin, additional, Park, Sae-Jin, additional, Yoon, Jeong Hee, additional, Joo, Ijin, additional, Lee, Kyoung-Bun, additional, and Kim, Haeryoung, additional

Published
2022
Full Text
View/download PDF

44. Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis

Author

Yoon, Jeong Hee, primary, Lee, Jeong Min, additional, Yu, Mi Hye, additional, Hur, Bo Yun, additional, Grimm, Robert, additional, Sourbron, Steven, additional, Chandarana, Hersh, additional, Son, Yohan, additional, Basak, Susmita, additional, Lee, Kyoung-Bun, additional, Yi, Nam-Joon, additional, Lee, Kwang-Woong, additional, and Suh, Kyung-Suk, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results